The company has posted a net loss of $37.32m for the first quarter 2011, or $0.26 loss per diluted share, compared to net loss of $38.2m, or $0.27 loss per diluted share, for the comparable period in last year.
Operating loss was $29.08m, compared to $32.84 during the same period in the previous year.
Amylin Pharma Finance senior vice president and chief financial officer Mark Foletta said they remain focused on their longer-term target of generating sustainable positive operating cash flow.
Amylin Pharma president and CEO Daniel Bradbury said in the coming quarters, they will submit their reply to the Bydureon complete response letter, as well as completing their regulatory application for the use of metreleptin in patients with lipodystrophy.